1. Introduction
===============

The recognition of a number of potential biases in clinical trials and meta-analyses in chronic pain has led to the adoption of new standards of evidence ([@b22]). These include using long duration studies (longer than 8 weeks), establishing a threshold for substantial benefit, typically that of at least 50% pain intensity reduction ([@b11]), and avoiding potential bias from imputation methods by using a true responder definition, whereby withdrawal for any reason is considered non-response ([@b26]). Part of the impetus behind these changes is the increasing recognition that a favourable response to treatment (high level of pain relief) is associated with improved sleep, less fatigue and depression, better function and ability to work, and higher quality of life; without substantial pain relief, these improvements are not seen ([@b16]; [@b28]; [@b41]).

A National Academy of Sciences report (Panel on [@b32]) recommended that imputation methods, such as last-observation-carried-forward (LOCF) and baseline observation carried forward (BOCF), should not be used as the primary approach to the treatment of missing data unless assumptions underlying them are scientifically justified. LOCF methods have been commonly used in analysing pain trial data where they may prove useful for group mean analyses. However, when a large percentage of patients withdraw because of lack of efficacy or adverse events ([@b25]), as is the case particularly with opioid use ([@b26]), a BOCF approach is warranted. In the case of chronic pain, the definition of a true responder as a patient with a high level of pain relief sustained for 12 weeks without intolerable adverse events (essentially a BOCF approach) is of practical clinical value.

We have limited knowledge of how true responder (BOCF) analyses impact estimates of treatment efficacy across chronic pain conditions, although an analysis of the effect of different imputation methods has been published for duloxetine in chronic low back pain (CLBP) trials (Liu-[@b19]). True responder analyses have been conducted for a number of chronic pain conditions, including osteoarthritis (OA), CLBP and ankylosing spondylitis with etoricoxib ([@b22], [@b24]; [@b33]), and fibromyalgia with pregabalin ([@b40]). There are only two known reports of true responder analyses for neuropathic pain, one from a pooled analysis of pregabalin in several neuropathic pain conditions ([@b36]) and a small trial in diabetic peripheral neuropathic pain (DPNP; [@b15]).

Here we report the responder analysis findings for a single serotonin-norepinephrine reuptake inhibitor (SNRI), duloxetine, in four distinct chronic pain conditions, OA, fibromyalgia, CLBP and DPNP. To the best of our knowledge, this is the first patient level analysis of an intervention assessed using important patient-centred pain outcomes and across four different chronic pain conditions. We report on speed of onset of effect, different levels of pain relief, and the effect of imputation method (LOCF and BOCF) on measures of treatment efficacy.

2. Methods
==========

Data for these analyses were from duloxetine randomized trials (Table [1](#tbl1){ref-type="table"}), conducted in OA \[studies HMFG, HMEP and HMGL ([@b8], [@b7]; [@b13]\], fibromyalgia (studies HMBO, HMCA, HMCJ and HMEF ([@b1], [@b2]; [@b6]; [@b35]); \], CLBP (studies HMEN, HMEO and HMGC ([@b38]; [@b37], [@b39])), and DPNP \[studies HMVAa, HMVAb and HMAW ([@b14]; [@b34]; [@b46]); \]. All were randomized, double blind, placebo-controlled studies, conducted in patients with at least moderate initial pain intensity (≥ 4 on a 0--10 numerical rating scale). Primary endpoints were measured at 12--15 weeks, apart from one study in OA where the primary endpoint was at 8 weeks. We used data from placebo and duloxetine doses of either 60 mg or 120 mg, and pooled data from different doses (60 mg and 120 mg) or dosing schedules, since there appear to be no differences in efficacy with various dosing regimens ([@b42]; [@b20]; [@b5]).

###### 

Data sources for analyses

  Chronic pain condition              Study identifier   Length of acute phase of study (weeks)                                      Dosing schedule                                                           Pain measures           Primary endpoint (timepoint)                            
  ----------------------------------- ------------------ --------------------------------------------------------------------------- ------------------------------------------------------------------------- ----------------------- ------------------------------------------------------- ---------------------------------------------------------------------------------------
  Osteoarthritis                      HMFG               13                                                                          60 Week 7: increased to120 based on reduction in BPI average pain score   Yes                     4, 7, 13                                                BPI 24-h average pain (13 weeks)
  HMEP                                13                 60 Week 7 randomized to 60 or 120                                           Yes                                                                       4,7,13                  Weekly mean of 24-h average pain (13 weeks)             
  HMGL                                10                 60 Week 3: increased to120 based on weekly mean of average pain score       Yes                                                                       3,4,8,10                Weekly mean of 24-h average pain, measured at 8 weeks   
  Fibromyalgia                        HMBO               12                                                                          120                                                                       No                      1,2,4,6,8,10,12                                         Fibromyalgia Impact Questionnaire (FIQ) pain item and the total FIQ scores (12 weeks)
  HMCA                                12                 60, 120                                                                     No                                                                        1,2,4,6,8,10,12         BPI 24-h average pain (12 weeks)                        
  HMCJ                                15                 20, 60, 120                                                                 No                                                                        1,2,4,7,11,15           BPI 24-h average pain and PGI-Improvement (15 weeks)    
  HMEF                                27                 60 Week 13: increased to120 based on reduction in BPI average pain score.   No                                                                        1,2,4,6,8,13,18,23,27   BPI 24-h average pain and PGI-Improvement (13 weeks)    
  Chronic low back pain               HMEN               13                                                                          60 Week 7: increased to 120 based on BPI                                  Yes                     4,7,13                                                  BPI 24-h average pain (13 weeks)
  HMEO                                13                 20, 60, 120                                                                 Yes                                                                       4,7,13                  Weekly mean of the 24-h average pain (13 weeks)         
  HMGC                                12                 60                                                                          Yes                                                                       3,6,9,12                BPI 24-h average pain (12 weeks)                        
  Diabetic painful neuropathic pain   HMAVa              12                                                                          60, 120                                                                   Yes                     4,8,12                                                  Weekly mean of the 24-h average pain (12 weeks)
  HMAVb                               12                 60, 120                                                                     Yes                                                                       4,8,12                  Weekly mean of the 24-h average pain (12 weeks)         
  HMAW                                12                 20, 60, 120                                                                 Yes                                                                       1,2,3,4,6,8,10,12       Weekly mean of the 24-h average pain (12 weeks)         

BPI, British Pain Inventory.

For analysis of time course response we used the weekly mean of average pain from daily diary records for the OA, CLBP, and DPNP datasets, and British Pain Inventory average pain for the fibromyalgia datasets. The outcome used was at least 50% pain intensity reduction using BOCF.

For the comparison of LOCF and BOCF imputation methods we used the primary endpoints of the individual studies (pain, measured on a 10-point numerical rating scale, see Table [1](#tbl1){ref-type="table"}), except in the case of Study HMBO. In all except the fibromyalgia studies the scale was administered both using a diary and at scheduled office visits; for fibromyalgia, the scale was administered only at scheduled office visits.

For the responder analyses, a responder was defined as a patient demonstrating a specified improvement in pain level, defined as at least 15, 30, 50 or 70% pain intensity reduction at the primary endpoint compared with baseline; these cutpoints have been used previously ([@b4]; [@b23], [@b24]; [@b40]), and the 30 and 50% cutpoints have been used to define moderate and substantial benefits ([@b11]). We also recorded responders with \<15%, 15--29%, 30--49% and ≥50% pain intensity reduction. Withdrawal from treatment for any reason was regarded as non-response and equivalent to BOCF, since imputation with the baseline level of pain intensity would exclude achievement of any of these levels of response. Responders were therefore considered true responders. We also calculated responders using LOCF imputation, where the last non-missing observation was carried forward from the time of withdrawal to the end of the trial.

In the analyses, we used the intention-to-treat definition as patients randomized and having received at least one dose of duloxetine or placebo; there were 4343 patients who were randomized and who had a baseline pain value (OA, *n* = 1011; fibromyalgia, *n* = 1332; CLBP, *n* = 982; DPNP, *n* = 1024) included in the responder analyses. Of these, 4238 (98%) had at least one pain recording after taking the first dose; because imputation is not possible without at least one post-treatment pain recording, this number was used as the denominator for the LOCF imputation analyses. Analyses were conducted according to painful condition, as different painful conditions can have different levels of response to placebo and active treatment ([@b29]). We calculated the number and percentage of responders by level of response for each treatment and time point and the number needed to treat (NNT) compared with placebo \[with 95% confidence interval (CI; [@b9]) \]. The relative risk or benefit with 95% CI was calculated using the fixed effects model ([@b30]) and considered statistically significant when the 95% CI did not include 1. NNT values were only calculated where there was a statistically significant difference between active and placebo treatments. Statistically significant differences between NNTs comparing different drugs or doses were calculated using the *z*-test ([@b44]), using data only from trials in which items being compared were both used.

Effects of excess adverse event withdrawal on percentage overestimation of NNT for LOCF imputation over true responder definition were calculated for duloxetine 60/120 mg for each chronic painful condition. The magnitude of the overestimation of treatment effect with LOCF (that is, the NNT increase defining withdrawal as nonresponse (BOCF) compared with use of LOCF imputation) was expressed as a percentage \[(100 × BOCF/LOCF imputation) − 100\] ([@b26]).

3. Results
==========

3.1 Time course of response
---------------------------

Fig. [1](#fig01){ref-type="fig"} shows the proportion of patients with at least 50% pain intensity reduction using BOCF (true responders) over 12 weeks in each of the conditions. This increased over time in all four painful conditions. For OA, CLBP and DPNP the proportion of patients with at least 50% pain intensity reduction reached 30--40% with duloxetine and 18--25% with placebo by week 12. For fibromyalgia, response rates with duloxetine reached 28% by week 2 with duloxetine, and 18% by week 6 with placebo.

![Percentage of patients achieving at least 50% pain intensity reduction with duloxetine 60/120 mg (black symbol) and placebo (white symbol) in four chronic pain conditions.](ejp0018-0067-f1){#fig01}

The time course of efficacy in the four painful conditions was somewhat different. For the outcomes of at least 50% pain intensity reduction for true responders, Fig. [2](#fig02){ref-type="fig"} demonstrates that consistent NNT values were achieved within 2 weeks for DPNP and fibromyalgia, and by weeks 4 or 5 for the chronic musculoskeletal conditions of OA and CLBP.

![NumberS needed to treat calculated over 12 weeks for at least 50% pain intensity reduction with duloxetine 60/120 mg compared with placebo.](ejp0018-0067-f2){#fig02}

3.2 Extent of response and effect of LOCF imputation
----------------------------------------------------

Table [2](#tbl2){ref-type="table"} shows the degree of response at ≥15%, ≥30%, ≥50% and ≥70% pain intensity reduction by the end of trial (8--12 weeks) for duloxetine 60/120 mg and placebo. The NNTs calculated at these different levels of response were typically large at very low and very high levels of response (Table [2](#tbl2){ref-type="table"}), and lower with response levels of at least 30% or at least 50% pain intensity reduction. This was the case whether true responses or LOCF imputation was used. However, NNTs calculated using the true responder definition were always numerically higher than those calculated using LOCF imputation, and in one of the 16 cases statistically higher.

###### 

Effect of response level and imputation on percentage of responders with duloxetine 60/120 mg and placebo, and NNTs calculated from responder rates

![](ejp0018-0067-tbl2)

Fig. [3](#fig03){ref-type="fig"} shows the distribution of response for each of the four pain conditions using BOCF true responders and intermediate levels of response. For each condition the distribution was distinctly non-Gaussian. With duloxetine or placebo, the majority of patients had either a very good response (≥50% pain intensity reduction) or poor response (\<15% pain intensity reduction); few had intermediate levels of pain intensity reduction. Average pain intensity reductions ranged between 24% and 38% with duloxetine, and 15% and 24% with placebo; the average reflected the experience of only a small proportion of patients.

![Patterns of pain intensity reduction for four different painful conditions using baseline observation carried forward true responders for duloxetine 60/120 mg (black symbol) and placebo (white symbol). Average pain intensity reductions with standard deviation were: osteoarthritis -- duloxetine 32 ± 32%, placebo 23 ± 28%; fibromylagia -- duloxetine 24 ± 35%, placebo 15 ± 30%; chronic low back pain -- duloxetine 30 ± 35%, placebo 24 ± 35%; painful peripheral diabetic neuropathy -- duloxetine 38 ± 37%, placebo 23 ± 35%.](ejp0018-0067-f3){#fig03}

3.3 Effect of withdrawal rates on overestimation of NNT with LOCF imputation
----------------------------------------------------------------------------

Table [3](#tbl3){ref-type="table"} shows withdrawals from treatment because of adverse events and lack of efficacy in each of the four chronic painful conditions. There were clear differences in withdrawal rate patterns between fibromyalgia and the other three conditions. For placebo, adverse event and lack of efficacy withdrawals were low (\<7.5% and \<4%, respectively) in DPNP, OA and CLBP studies, but higher (\>10%, \>11%) in fibromyalgia studies. Adverse event withdrawals with duloxetine were higher than with placebo (\>14%), but lack of efficacy withdrawals lower in each condition.

###### 

Study withdrawal with duloxetine 60/120 mg and placebo in four painful conditions

  Condition                                Placebo   Duloxetine          
  ----------------------------- --- ------ --------- ------------ ------ -----
  Osteoarthritis                3   1011   7.3       3.2          15.7   1.0
  Fibromyalgia                  4   1332   10.5      11.8         18.4   5.5
  Chronic low back pain         3   982    6.4       3.6          16.7   1.9
  Painful diabetic neuropathy   3   1024   5.0       2.9          13.6   1.0

Previous research has shown that an excess of adverse event withdrawals is the major driver for overestimation of treatment effect with LOCF compared with BOCF ([@b26]) For each of these four chronic pain conditions, the relationship between adverse event withdrawals with active drug over placebo and overestimation of treatment effect with LOCF imputation over BOCF true responders was consistent with that relationship.

4. Discussion
=============

To the best of our knowledge, this is the first patient-level analysis of a single intervention (duloxetine 60/120 mg) assessed using important patient-centred pain outcomes and across four different chronic pain conditions, spanning neuropathic pain, musculoskeletal pain and fibromyalgia. The strength of the analysis is that the data come from well-conducted randomized, double-blind trials, of trial duration longer than 8 weeks, and with large enough treatment arms to limit some known biases, such as sample size ([@b31]). The analysis met all the criteria for reporting unbiased data in chronic pain ([@b22]), and the effect of potentially large biases from imputation method could be examined and eliminated ([@b26]).

The key findings from this analysis were that:The proportion of patients recording at least 50% pain intensity reduction plateaued after 2--6 weeks for fibromyalgia, and 8--12 weeks for the other conditions (Fig. [1](#fig01){ref-type="fig"}).The duloxetine-specific benefit (NNT for at least 50% pain intensity reduction) was fairly constant after about 2 weeks for DPNP and fibromyalgia, and after about 4 or 5 weeks for OA and CLBP (Fig. [2](#fig02){ref-type="fig"}).In all conditions, responses were bimodal, with patients generally experiencing either very good or very poor pain relief (Fig. [3](#fig03){ref-type="fig"}).LOCF imputation produced numerically and sometimes statistically better (lower) NNTs than use of BOCF (true response); the latter combines both the success of high levels of pain relief with the failure to experience pain relief on withdrawal of the drug for any reason and is probably more reflective of clinical practice experience ([@b26]).

It is instructive to compare these results for duloxetine with what is known about other drugs used in chronic pain conditions, despite the lack of any comprehensive background information in any individual painful condition. For example, findings have been published on pain relief with non-steroidal anti-inflammatory drugs (NSAIDs) in OA ([@b23]), CLBP ([@b24]), and ankylosing spondylitis ([@b33]), as well as pregabalin in fibromyalgia ([@b41]); in all cases, proportion of responders remained reasonably constant after about 2 weeks of treatment. These earlier findings are similar to those seen here with duloxetine use in fibromyalgia (Fig. [1](#fig01){ref-type="fig"}), but are in contrast to those seen with duloxetine in DPNP, OA and CLBP, where the percentage of responders rose consistently throughout the trial periods. Given our current experience and knowledge, it is not possible to determine whether the differences are a feature of the painful condition, the nature of responses with SNRIs, or some otherwise-overlooked feature of the way the trials were conducted. More analyses like this for duloxetine are needed to fully understand time courses of action of different drugs in chronic pain.

Previous work has also demonstrated a tendency for NNTs to increase over a 12-week study period, sometimes quite substantially, with NSAID use in CLBP ([@b24]), with ibuprofen, but not other NSAID, use in OA ([@b23]), and with pregabalin use in fibromyalgia ([@b41]). For duloxetine, by contrast, NNTs fell during the first 2--5 weeks of treatment, and were consistent thereafter in all four conditions, much as has been reported with NSAID use in ankylosing spondylitis ([@b33]). Again, different circumstances seem to deliver different patterns of response.

What is consistent between the current findings and those from previous analyses is the bimodal distribution of response by the end of trial, with the majority of patients having either a substantial level of pain relief or very little; few experienced the 'average' result. Averages are not appropriate descriptors for these data, especially when the standard deviation of the average response is of the same magnitude as, or even larger than, the average, as here (Fig. [3](#fig03){ref-type="fig"}).

The consistency of the bimodal distribution is remarkable, in this study over four different chronic pain conditions for duloxetine, and generally in other studies across different pharmacological interventions in acute pain ([@b27]), NSAIDs in musculoskeletal conditions ([@b23], [@b24]; [@b33]) and amitriptyline in neuropathic pain ([@b21]). It emphasizes most strongly that currently available analgesics can deliver substantial benefits in pain relief (≥50% pain intensity reduction) for a minority of patients with chronic pain, and this level of pain relief is known to be accompanied by large improvements in sleep, depression, fatigue, function, quality of life and ability to work ([@b16]; [@b28]; [@b41]).

Another feature where the results of this analysis are generally in keeping with those reported for other drugs is in the relationship between NNT calculated using either BOCF or LOCF and the degree of pain intensity reduction. The finding of lower (better) NNTs with the 30% and 50% cutpoints compared with lower or higher cutpoints is similar to the findings with etoricoxib in OA and ankylosing spondylitis ([@b23]; [@b33]), and with pregabalin in fibromyalgia ([@b40]). This indicates that the outcomes defined as moderate and substantial benefit to patients ([@b11]) are those with the greatest sensitivity to distinguish efficacy, similar to acute pain ([@b27]).

What we have, then, are consistent findings across chronic pain studies for the bimodal distribution of pain response and an overestimation of treatment effect in the presence of high adverse event withdrawals with active drug. This has a potentially major impact on the development of guidelines unless all potential sources of bias are considered so that like is only compared with like. What we do not have is consistency in terms of time to response or evolution of efficacy, which seem to differ between conditions and drugs; this may be the type of drug, or the condition, or an interaction between both. We do not know enough to be sure.

This analysis of responder rates of duloxetine in four different chronic pain conditions is possibly unique, and has the potential to induce a radical shift in everyday chronic pain treatment. Currently available medications for symptomatic treatment of chronic pain are traditionally grouped into different medication categories -- NSAIDs, opioids, anticonvulsants and antidepressants. These categories are reflections of either the pathophysiological concept behind the particular pain category (e.g. nociceptive vs. inflammatory vs. neuropathic) or where these treatments were first developed. Chronic pain treatments have often 'borrowed' drugs developed in other areas as much as using therapies developed on a mechanistic basis.

If we could identify individual patients with any pain condition in whom specific biological mechanisms were responsible for their pain (nociceptive, inflammatory, neuropathic or some other unknown mechanism), individualized treatment specifically targeting those mechanisms might be employed. Any practical method of ascertaining which mechanism was responsible for an individual patient\'s pain (Jensen and Baron, [@b17]; Tölle and Backonja, [@b43]) would demand a paradigm shift over current clinical practice of trying different drugs in individual patients to find one that worked. In this context, not surprisingly, a single drug can have substantial effects in many different chronic pain conditions, if the appropriate mechanism, e.g. central sensitization or imbalanced descending control, is involved and properly met by the drug. These theoretical considerations together with clinical observations open up a much broader and favourable treatment regimen than currently typically practiced.

Thoughtful analyses have demonstrated similar results for pharmacological interventions in chronic pain, which is that at best half of patients treated with any single drug obtains 'moderate' pain relief ([@b10]; [@b12]), although this proportion falls when higher levels of pain relief and evidence standards are applied ([@b22], [@b26]). In general, though, drugs tend to have broadly equivalent efficacy in particular conditions, as is seen with duloxetine and amitriptyline ([@b18]), or pregabalin and amitriptyline ([@b3]). Importantly, this broad similarity in overall efficacy does not exclude individual patients responding to one drug but not another, as with amitriptyline and nortriptyline ([@b45]), or preferring one drug over another, as with duloxetine and amitriptyline ([@b18]). Drugs may have equal efficacy on average, but not in individuals.

5. Conclusion
=============

This analysis confirms several key elements of evidence regarding our understanding and use of clinical trial data to support clinical practice. LOCF probably consistently overestimates the beneficial effects of treatment, and studies of short duration may provide inaccurate results. A true responder analysis of data from studies of longer duration (6--8 or more weeks), and using the ideal outcome of at least 50% pain intensity reduction are needed before we can be confident of making appropriate indirect comparisons between treatments, especially in guideline development. Last but not least, the clinical data show that the current concept of using certain drug classes for specific chronic pain states should be abandoned.
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